Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system’s inhibitor denosumab vs. bisphosphonates
Andrea Casabella, Francesca Paladin, Claudia Bighin, Silvia Ottaviani, Cristina Marelli, Marta Ponzano, Alessio Signori, Giuseppe Murdaca, Maurizio Cutolo, Luigi Molfetta, Alessio Nencioni, Sabrina Paolino, Lucia Del Mastro, Fiammetta Monacelli
Topics & Concepts
DenosumabMedicineBreast cancerAromatase inhibitorInternal medicineBone remodelingBone mineralOsteoporosisRANKLEndocrinologySarcopeniaOncologyAromataseOsteoclastLetrozoleCancerReceptorActivator (genetics)Bone health and treatmentsBone health and osteoporosis researchBone Metabolism and Diseases